Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -196.36 | — | 359.36 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9.19 | 6.66 | 7.85 | 4.95 | 4.93 | 5.03 | 5.15 | 5.18 | 4.26 | 4.96 | 6.80 | 6.57 | 7.16 |
| — | +32.4% | +52.3% | -4.5% | +15.9% | +1.4% | -24.2% | -21.1% | -40.5% | -24.4% | -30.4% | -26.6% | -46.4% | |
| P/B Ratio | 14.72 | 12.60 | 14.31 | 9.92 | 9.44 | 8.86 | 8.03 | 7.05 | 5.02 | 5.55 | 4.83 | 12.54 | 6.41 |
| — | +42.2% | +78.1% | +40.6% | +87.9% | +59.7% | +66.4% | -43.8% | -21.6% | +7.7% | +11.3% | +121.7% | +1.3% | |
| P/FCF | 87.28 | 181.32 | 26.45 | 53.10 | — | — | — | — | 19.39 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 73.31 | 121.61 | 614.19 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 351.48 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Mirum Pharmaceuticals, Inc.'s operating margin was -3.1% in Q4 2025, down 5.0 pp QoQ and up 21.3 pp YoY. The trailing four-quarter average of -4.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 68.1% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.8% | 129.5% | 80.8% | 81.7% | 79.4% | 77.1% | 77.0% | 74.0% | 74.2% | 64.0% | 78.6% | 81.8% | 84.2% |
| — | +68.1% | +5.0% | +10.3% | +6.9% | +20.4% | -2.0% | -9.5% | -11.9% | -23.7% | -6.9% | -4.4% | +3.8% | |
| Operating Margin | -4.2% | -3.1% | 2.0% | -3.9% | -13.6% | -24.4% | -14.0% | -31.1% | -38.2% | -46.8% | -52.7% | -64.7% | -85.9% |
| — | +87.4% | +113.9% | +87.5% | +64.4% | +48.0% | +73.4% | +51.9% | +55.5% | +61.7% | +69.9% | +64.0% | +66.2% | |
| Net Margin | -4.5% | -3.8% | 2.2% | -4.6% | -13.2% | -23.9% | -15.8% | -31.6% | -36.5% | -51.3% | -49.4% | -197.5% | -95.4% |
| — | +83.9% | +113.9% | +85.5% | +64.0% | +53.3% | +68.1% | +84.0% | +61.7% | +60.7% | +74.0% | -28.2% | +66.4% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.6% | -1.9% | 1.1% | -2.4% | -6.4% | -10.4% | -6.2% | -10.6% | -10.5% | -13.8% | -13.6% | -67.4% | -21.3% |
| — | +81.8% | +117.2% | +77.4% | +38.9% | +24.5% | +54.5% | +84.2% | +50.8% | +41.1% | +46.8% | -174.8% | +33.4% | |
| ROA | -3.1% | -0.7% | 0.4% | -0.8% | -2.2% | -3.6% | -2.1% | -3.8% | -3.9% | -5.5% | -4.3% | -19.1% | -8.8% |
| — | +80.2% | +117.9% | +77.9% | +44.6% | +35.3% | +50.3% | +80.3% | +55.7% | +45.9% | +60.1% | -103.6% | +31.3% | |
| ROIC | -5.1% | -1.0% | 0.6% | -1.1% | -3.5% | -5.6% | -3.0% | -6.6% | -7.8% | -9.0% | -10.4% | -19.9% | -19.4% |
| — | +81.6% | +119.4% | +83.4% | +55.7% | +37.5% | +71.3% | +66.9% | +59.9% | +55.9% | +59.3% | +48.2% | +38.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Mirum Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 23.3x, down from 36.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 13.9% YoY to 2.67x, tightening the short-term liquidity position. Debt/Equity has declined for 5 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.01 | 1.01 | 1.09 | 1.25 | 1.36 | 1.41 | 1.37 | 1.38 | 1.31 | 1.24 | 1.14 | 3.92 | 0.01 |
| — | -28.4% | -20.3% | -9.6% | +3.7% | +13.6% | +19.6% | -64.7% | +9296.5% | +7944.4% | +9188.5% | +19002.9% | -37.8% | |
| Debt / EBITDA | — | 23.34 | 36.79 | 298.87 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.67 | 2.67 | 3.31 | 3.13 | 3.22 | 3.10 | 3.34 | 3.28 | 3.68 | 4.45 | 5.20 | 6.59 | 3.53 |
| — | -13.9% | -0.9% | -4.4% | -12.4% | -30.3% | -35.8% | -50.3% | +4.2% | +51.5% | +24.1% | +102.2% | -21.5% | |
| Quick Ratio | 2.55 | 2.55 | 3.16 | 2.97 | 3.04 | 2.93 | 3.15 | 3.09 | 3.47 | 4.19 | 4.91 | 6.44 | 3.39 |
| — | -12.9% | +0.2% | -3.9% | -12.3% | -30.2% | -35.7% | -52.0% | +2.4% | +47.0% | +20.9% | +103.9% | -23.7% | |
| Interest Coverage | — | -0.25 | 0.72 | -1.39 | -4.22 | -6.77 | -3.54 | -6.79 | -7.40 | -9.15 | -7.04 | -6.51 | -6.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonMirum Pharmaceuticals, Inc.'s current P/E is -196.4x. The average P/E over the last 1 quarters is 359.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mirum Pharmaceuticals, Inc.'s current operating margin is -4.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mirum Pharmaceuticals, Inc.'s business trajectory between earnings reports.